Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 135.8% | 175.9% | 70% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 98.2% | -89.6% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -83.6% | -173% | -455.8% | -768.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -85.4% | -196% | -452.7% | -759.5% |
| EPS Diluted | -0.11 | -0.16 | -0.18 | -0.2 |
| % Growth | 31.3% | 11.1% | 10% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |